Sangamo Therapeutics, Inc.
7000 Marina Blvd
Brisbane
CA
94005
United States
Tel: (510) 970-6000
Website: https://www.sangamo.com/
Email: hr@sangamo.com
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms – gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. At Sangamo, we are passionate in developing genomic medicines to transform the lives of patients with serious diseases. We transform lives by building a robust, sustainable, differentiated, innovative, and high value genomic medicine pipeline that addresses patients with life-limiting conditions. Sangamo takes pride in being the first to edit endogenous human genes, first to treat patients with gene edited T cells, and first to treat patients with in vivo genome editing. Our top priority is to meet the needs of patients with commitment and compassion. Along with our commitment to science and to our patients, we also endeavor to create an inclusive environment that promotes and values diversity. Sangamo is a company where individuals can flourish, grow and develop their expertise.
We are seeking top talent to join our mission. Let’s build a better future together.
Stock Symbol: SGMO
634 articles about Sangamo Therapeutics, Inc.
-
Sangamo BioSciences, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
2/5/2009
-
Sangamo BioSciences, Inc. Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
2/3/2009
-
New AIDS Approach Disrupts Patient's DNA, Sangamo BioSciences, Inc. Announces
2/3/2009
-
Sangamo BioSciences, Inc. Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
1/29/2009
-
Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
1/12/2009
-
Sangamo BioSciences, Inc. Announces License Agreement With Pfizer Inc. (JOBS) for Zinc Finger Nucleases for Protein Production
12/22/2008
-
Sangamo BioSciences, Inc. Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
11/20/2008
-
Sangamo BioSciences, Inc. Drug SB-509 Fails Midstage Study
11/11/2008
-
Sangamo BioSciences, Inc. Reports Third Quarter 2008 Financial Results
10/31/2008
-
Sangamo BioSciences, Inc. Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN
10/29/2008
-
Sangamo BioSciences, Inc. Announces Presentation of Data From Diabetic Neuropathy Clinical Trials Positive Interim Data
9/15/2008
-
Sangamo BioSciences, Inc. Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis
9/3/2008
-
Sangamo BioSciences, Inc. Reports Second Quarter 2008 Financial Results
7/24/2008
-
Sangamo BioSciences, Inc. Announces Second Quarter Conference Call and Webcast
7/17/2008
-
Sangamo BioSciences, Inc. (JOBS) and Sigma-Aldrich Corporation Announce Research and License Agreement With Roche (JOBS)
7/9/2008
-
Sangamo BioSciences, Inc. Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
6/30/2008
-
Dow AgroSciences LLC Inks Biotech Deal with Sangamo BioSciences, Inc.
6/19/2008
-
Sangamo BioSciences, Inc. Announces Completion of Accrual and Expansion Plans for SB-509-701 Phase 2 Clinical Trial for Treatment of Moderate to Severe Diabetic Neuropathy
6/6/2008
-
Dow AgroSciences LLC, Sangamo BioSciences, Inc. Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
6/5/2008
-
Sangamo BioSciences, Inc. Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
5/19/2008